Michelle Morris on Muck Rack

Michelle Morris

As seen in: Nature, The Guardian, Associated Press: Press Releases, MDPI, Nutrition Journal, The International Journal of Behavioral Nutrition and Physical Activity, Royal Society of Chemistry, South Florida Media Network, Bizcommunity, EIN Presswire and
Publisher Make It Better Media
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michelle

Contact Michelle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

|
By Carole Harris, Michelle Morris, Danka S Zebic
| UroToday Verified
Anti-PD1 immune checkpoint inhibitors (ICI) are effective in clear-cell renal-cell carcinoma (ccRCC). Preliminary data suggest inhibition of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) signaling may potentiate ICI efficacy. We evaluated the activity and safety of the RANKL-inhibitor denosumab with pembrolizumab in people with pretreated advanced ccRCC.
Open in Who Shared Issue with article?

Michigan Native Michelle S. Morris Publishes Debut Novel Comes Around

|
By Michelle Morris
| Coast to Coast Tribune
Author Michelle S. Morris Comes Around by Michelle S. Morris A Journey of Resilience, Self-Discovery, and the Enduring Power of Home WEST BRANCH, MI, UNITED STATES, June 10, 2025 / EINPresswire.com/ -- Comes Around, the first fiction book from former White House staffer and corporate communications executive and strategist Michelle S.
Open in Who Shared View Duplicates (25) Issue with article?

SCAI 25: AVENTUS Thrombectomy System: Autologous Blood Reinfusion for Pulmonary Embolism

|
By Jun Li, James Krzowski, Jonathan McCall Verified, Michelle Morris
| RadcliffeCardiology.com Verified
Video Published: Views: 8 Likes: 0 Average (ratings) SCAI 25 - Outcomes from the AVENTUS thrombectomy system for intermediate-risk pulmonary embolism show a significant improvement in right ventricular to left ventricular ratio reduction compared to the baseline measurements. The AVENTUS thrombectomy system also met the trial's safety outcome with no device-related major adverse events at 48 hours post-procedure.
Open in Who Shared Issue with article?
See all 50 licensed articles (62 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified